T. Rowe Price Associates’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-3,809,859
| Closed | -$181M | – | 3091 |
|
|
2025
Q3 | $181M | Sell |
3,809,859
-699,466
| -16% | -$33.9M | 0.02% | 484 |
|
|
2025
Q2 | $241M | Sell |
4,509,325
-307,766
| -6% | -$14M | 0.03% | 397 |
|
|
2025
Q1 | $195M | Buy |
4,817,091
+495,119
| +11% | +$21M | 0.02% | 424 |
|
|
2024
Q4 | $120M | Buy |
4,321,972
+513,613
| +13% | +$15.6M | 0.01% | 534 |
|
|
2024
Q3 | $109M | Sell |
3,808,359
-337,992
| -8% | -$8.81M | 0.01% | 549 |
|
|
2024
Q2 | $97.3M | Buy |
4,146,351
+85,872
| +2% | +$1.84M | 0.01% | 548 |
|
|
2024
Q1 | $103M | Buy |
4,060,479
+384,555
| +10% | +$9.24M | 0.01% | 546 |
|
|
2023
Q4 | $85.8M | Sell |
3,675,924
-134,270
| -4% | -$2.65M | 0.01% | 577 |
|
|
2023
Q3 | $193M | Buy |
3,810,194
+520,551
| +16% | +$24.2M | 0.03% | 398 |
|
|
2023
Q2 | $154M | Buy |
3,289,643
+665,963
| +25% | +$30.5M | 0.02% | 437 |
|
|
2023
Q1 | $100M | Buy |
2,623,680
+222,643
| +9% | +$9.93M | 0.02% | 510 |
|
|
2022
Q4 | $132M | Buy |
2,401,037
+938,613
| +64% | +$40.2M | 0.02% | 449 |
|
|
2022
Q3 | $49.8M | Buy |
1,462,424
+1,007,122
| +221% | +$15.4M | 0.01% | 647 |
|
|
2022
Q2 | $4.3M | Sell |
455,302
-62
| -0% | -$646 | ﹤0.01% | 1441 |
|
|
2022
Q1 | $6.46M | Sell |
455,364
-704,166
| -61% | -$12.3M | ﹤0.01% | 1425 |
|
|
2021
Q4 | $24.5M | Buy |
1,159,530
+7,931
| +0.7% | +$176K | ﹤0.01% | 1235 |
|
|
2021
Q3 | $25.7M | Sell |
1,151,599
-2,604
| -0.2% | -$58.9K | ﹤0.01% | 1230 |
|
|
2021
Q2 | $28.6M | Buy |
1,154,203
+261,057
| +29% | +$7.33M | ﹤0.01% | 1208 |
|
|
2021
Q1 | $25.9M | Buy |
893,146
+235,691
| +36% | +$7.13M | ﹤0.01% | 1210 |
|
|
2020
Q4 | $17M | Buy |
657,455
+154,974
| +31% | +$4.31M | ﹤0.01% | 1256 |
|
|
2020
Q3 | $15.5M | Buy |
502,481
+355,949
| +243% | +$12.4M | ﹤0.01% | 1207 |
|
|
2020
Q2 | $3.65M | Sell |
146,532
-92,946
| -39% | -$2.12M | ﹤0.01% | 1423 |
|
|
2020
Q1 | $5.08M | Buy |
239,478
+13,079
| +6% | +$281K | ﹤0.01% | 1341 |
|
|
2019
Q4 | $5.03M | Buy |
226,399
+22,486
| +11% | +$465K | ﹤0.01% | 1394 |
|
|
2019
Q3 | $4.64M | Buy |
203,913
+2,413
| +1% | +$56.1K | ﹤0.01% | 1389 |
|
|
2019
Q2 | $3.86M | Buy |
+201,500
| New | +$3.82M | ﹤0.01% | 1431 |
|
Other funds holding AKRO
T. Rowe Price Associates's AKRO Position: Q4 2025 in Review
T. Rowe Price Associates sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 3,809,859 shares — an estimated $181M sold.
T. Rowe Price Associates first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $241M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- T. Rowe Price Associates reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 3,809,859 Akero Therapeutics shares in Q4 2025, an estimated $181M.
- T. Rowe Price Associates first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- T. Rowe Price Associates's Akero Therapeutics position peaked at $241M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.